Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lucid Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Lucid Diagnostics Inc.’s stock price such as:

• Lucid Diagnostics Inc.’s current stock price and volume
• Why Lucid Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for LUCD from analysts
• LUCD’s stock price momentum as measured by its relative strength

About Lucid Diagnostics Inc. (LUCD)

Before we jump into Lucid Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Want to learn more about Lucid Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lucid Diagnostics Inc..

Lucid Diagnostics Inc.’s Stock Price as of Market Close

As of December 09, 2025, 4:00 PM, CST, Lucid Diagnostics Inc.’s stock price was $1.100.

Lucid Diagnostics Inc. is up 4.76% from its previous closing price of $1.050.

During the last market session, Lucid Diagnostics Inc.’s stock traded between $1.090 and $1.150. Currently, there are approximately 108.18 million shares outstanding for Lucid Diagnostics Inc..

Lucid Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lucid Diagnostics Inc. Stock Price History

Lucid Diagnostics Inc.’s (LUCD) price is currently up 3.77% so far this month.

During the month of December, Lucid Diagnostics Inc.’s stock price has reached a high of $1.150 and a low of $0.992.

Over the last year, Lucid Diagnostics Inc. has hit prices as high as $1.800 and as low as $0.750. Year to date, Lucid Diagnostics Inc.’s stock is up 34.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lucid Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of December 09, 2025,, no analysts have changed their rating of Lucid Diagnostics Inc.’s stock over the last month.

Additionally, you'll want to evaluate Lucid Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lucid Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lucid Diagnostics Inc. (LUCD) by visiting AAII Stock Evaluator.

Relative Price Strength of Lucid Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 09, 2025, Lucid Diagnostics Inc. has a weighted four-quarter relative price strength of 4.13%, which translates to a Momentum Score of 71 and is considered to be Strong.

Want to learn more about how Lucid Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lucid Diagnostics Inc. Stock Price: Bottom Line

As of December 9, 2025, Lucid Diagnostics Inc.’s stock price is $1.100, which is up 4.76% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lucid Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.